Stay updated on Pembrolizumab for Recurrent Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.
Latest updates to the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page
- Check7 days agoChange DetectedA new Locations section appears with Texas as a site, replacing the earlier Texas Locations entry; the HHS Vulnerability Disclosure link is removed.SummaryDifference0.2%
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedPublications section wording updated to replace 'the study results' with 'the results of the study' and to add a version tag (Revision: v3.3.2) while removing the older tag (v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check43 days agoChange DetectedThe government funding and operating status notice has been removed from the page, while core study details, eligibility criteria, and contact information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check65 days agoChange DetectedNo significant changes detected in the page contents or structure between screenshots; the primary study details remain the same.SummaryDifference0.4%
- Check86 days agoChange DetectedVersion bump to v3.2.0 accompanied by a government-operating-status notice; replaces the earlier v3.1.0 tag.SummaryDifference3%
- Check93 days agoChange DetectedUpdated the site/page version from v3.0.2 to v3.1.0, indicating a new release without other substantive content changes.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab for Recurrent Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.